The Dermatology Digest

MARCH 5, 2024

.” Coral Gables, FL-based dermatologist Joely Kaufman, MD, adds, “The results from the clinical trials for letibotulinumtoxinA demonstrate efficacy, and a convincing safety profile in the treatment of glabellar lines. Hugel resubmitted its application in October 2022 and was denied approval again in 2023. and Europe.

Branding 74

Branding Injections Safety Facials 74

The Dermatology Digest

JANUARY 30, 2024

Five investigators have received funding through the 2023 PeDRA Research Grants, Career Bridge Research Grant, Pediatric Alopecia Areata Challenge Grant, and Childhood Eczema Challenge Grant programs. The post And the Winners Are…PeDRA Announces 2023 Grant Recipients appeared first on The Dermatology Digest.

Partnerships 36

Partnerships Eczema Hospital Dermatology 36

New Age Spa Institute

JULY 6, 2023

Las Vegas, known as the entertainment capital of the world, welcomed beauty professionals and skin care enthusiasts from across the globe for the highly anticipated International Esthetics Cosmetics Skincare Conference (IECSC) 2023. Let’s dive into the captivating highlights of this exceptional conference. License renewal.

Esthetics 52

Esthetics Skincare Esthetician Medical Esthetics 52

The Dermatology Digest

JANUARY 13, 2025

Proof-of-concept efficacy and safety data from a Phase1bstudy of rezpegaldesleukin in atopic dermatitis patients were presented at the 2023 EADV Congress. This trial was initiated inOctober 2023.

Dermatitis 36

Dermatitis Clinic Eczema Therapy 36

The Eco Well Blog

MAY 8, 2023

He’s held key R&D, regulatory, quality, product safety, clinical & scientific affairs positions at Ciba, Dial, Henkel, ITG Brands, Newell Rubbermaid. He’s been active in helping shape & influence Congressional cosmetic and OTC drug legislative reform initiatives.

Legal 52

Legal Technology Sun Protection Branding 52

The Dermatology Digest

DECEMBER 14, 2023

The National Eczema Association (NEA) announced the recipients for its 2023 research grants. The 2023 research grantees include: The Champion Research Grant encourages researchers to continue research on emerging or ongoing challenges in eczema or bring their expertise to the field of eczema.

Eczema 36

Eczema Dermatitis Hospital Networking 36

Les Nouvelles Esthetics & Spa

JANUARY 31, 2024

We invest heavily in their training, focusing on the intricacies of our products and safety protocols. Without the burden of licensing requirements, we’ve fostered a diverse group of talented individuals. For many, Pure Glow has been a stepping stone to greater achievements in the beauty industry. What is your plan for company growth?

Branding 78

Branding Sales Office Safety 78

The Dermatology Digest

MARCH 3, 2025

The long-term safety and efficacy of B-VEC is further supported by results from the Companys open label extension study completed in the United States as well as real-world experience with B-VEC since launching the United States in 2023.

Therapy 36

Therapy Clinic Hospital Dermatology 36

The Dermatology Digest

FEBRUARY 10, 2025

Proof-of-concept efficacy and safety data from a Phase 1b study of rezpegaldesleukin in AD patients were presented at the 2023 European Academy of Dermatology and Venereology Congress. “We are pleased that rezpegaldesleukin has been designated a Fast Track product,” says Jonathan Zalevsky, Ph.D.,

Dermatitis 36

Dermatitis Therapy Office Safety 36

The Dermatology Digest

DECEMBER 27, 2023

The Skin of Color Society (SOCS) reports that 2023 was a year of exceptional progress for its mission to change the landscape for people with darker skin tones through research, education, mentorship, and advocacy. 2023 Highlights December 2023: The SOCS Meeting the Challenge Summit: Population Descriptors in Dermatology Research Studies.

Education 36

Education Innovations Dermatology Clinic 36

The Dermatology Digest

JANUARY 29, 2024

Food and Drug Administration (FDA) for treatment of seborrheic dermatitis in adult and pediatric patients 9 years of age and older in December 2023. Zoryve foam was well-tolerated with a favorable safety and tolerability profile. It is the first drug approved for seborrheic dermatitis with a new mechanism of action in over two decades.

Dermatitis 74

Dermatitis Safety Dermatology Treatments 74

The Dermatology Digest

APRIL 4, 2024

The safety profile of Bimzelx was consistent with previous studies with no new safety signals observed. in October 2023 for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. In addition, improvements increased for patients in these studies over 48 weeks.

Safety 57

Safety Injections Clinic Therapy 57

The Dermatology Digest

MAY 16, 2024

Sonelokimab in PsA For PsA, Phase 3 initiation is anticipated in Q4 2024 following the announcement in March 2024 of the full dataset from the global Phase 2 ARGO trial (M1095-PSA-201) evaluating the efficacy and safety of the Nanobody sonelokimab over 24 weeks in patients with active PsA.

Safety 68

Safety Clinic Dermatology Office 68

The Dermatology Digest

FEBRUARY 14, 2024

This follows its designation as a Breakthrough Therapy for the treatment of pruritus associated with prurigo nodularis, originally granted in December 2019 and reconfirmed in March 2023. Nemolizumab was generally well tolerated and its safety profile was similar to placebo across the OLYMPIA and ARCADIA clinical trial programs.

Dermatitis 78

Dermatitis Clinic Safety Dermatology 78

The Dermatology Digest

MARCH 22, 2024

1,2 Benzene has become a more recent focus of attention related to safety concerns, with an increase in independent product testing and also updated regulations by the Food and Drug Administration related to benzene. Public safety is the first priority of the AARS. Right now, there are many questions about this issue. pp 9767-9777.

Rosacea 64

Rosacea Document Safety Ingredients 64

Aesthetics Advisor

DECEMBER 14, 2023

For almost 90% of the most common pesticides, the agency has neglected to apply the Food Quality Protection Act–mandated children’s health safety factor to the allowable limits. Newcomers on the Dirty Dozen list for 2023 are blueberries and green beans, now ranked as No. Strawberries have remained in the No. 12, respectively.

Diet 36

Diet Document Download Safety 36

The Dermatology Digest

APRIL 30, 2024

Lebrikizumab Timeline October 2023 The U.S. There were no concerns with lebrikizumab’s clinical data package, safety, or label.

Dermatitis 36

Dermatitis Safety Clinic Dermatology 36

Aesthetics Advisor

AUGUST 7, 2023

The 2023 report from the World Obesity Federation estimates that the economic impact of overweight and obesity will surpass $4.3 In April 2023, a spokesperson for Novo Nordisk, maker of semaglutide, said the drugs are now available in pharmacies nationwide. A broad range of drug interventions can help. trillion annually by 2035.

Diet 36

Diet Extractions Medical Sustainability 36

Aesthetics Advisor

OCTOBER 7, 2023

For example, in September 2023, it was discovered that counterfeit versions of Pure Encapsulations L-glutamine and NatureMD’s GutConnect 365 were sold Amazon. In August 2023, it was revealed that a counterfeit version of Bausch + Lomb’s PreserVision AREDS 2 Eye Vitamin & Mineral supplement had been sold on Amazon.

Branding 69

Branding Document Product Review Safety 69

The Eco Well Blog

JUNE 14, 2024

2023), when consumers had the option between “mineral” and “chemical” sunscreens, when blinded, overwhelmingly they preferred the “chemical” sunscreen. So now we’re okay with less safety data over an ingredient that has more safety data? Sunscreen application, safety, and sun protection: the evidence. Colantonio, S.,

Sun Protection 52

Sun Protection Ingredients Safety Marketing 52

The Dermatology Digest

SEPTEMBER 30, 2024

In February 2023, Fresenius Kabi and Formycon entered into a global commercialization partnership for the ustekinumab biosimilar candidate covering key global markets. Otulfi demonstrated comparable efficacy, safety, pharmacokinetics and immunogenicity to Stelara in patients with moderate to severe psoriasis vulgaris.

Portfolios 36

Portfolios Partnerships Marketing Safety 36

New Age Spa Institute

JUNE 8, 2023

INGLOT places importance on ingredient safety, ethical practices and sustainability. The next full-time professional makeup certification is from August 21, 2023 to August 31, 2023, Monday through Thursday, 9:00 a.m. They also offer a wide selection of vegan and cruelty-free cosmetic options. to 5:00 p.m. to 5:00 p.m.

Makeup 52

Makeup Training Esthetics Hydration 52

Aesthetics Advisor

AUGUST 6, 2023

More research is being done to determine the safety of the keto diet in the long term. Anyone taking this medication should avoid the keto diet ( 40 Trusted Source , 41 Trusted Source ). Keep your doctor informed of your eating plan to guide your choices.

Diet 36

Diet Medical Management Sustainability 36

The Dermatology Digest

JULY 10, 2024

The treatment was approved by the European Commission and the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) in December 2023. The letter stated no concerns about the clinical data package, safety, or label for lebrikizumab.

Dermatitis 36

Dermatitis Safety Dermatology Marketing 36

The Dermatology Digest

APRIL 23, 2024

The CRL did not identify any deficiencies related to the clinical efficacy or clinical safety data in the BLA, and the FDA did not request any new clinical trials or clinical data to support the approval of pz-cel. The BLA for pz-cel was accepted for filing and granted priority review designation by the FDA in November 2023.

Marketing 36

Marketing Safety Clinic Sustainability 36

The Dermatology Digest

MAY 1, 2024

The low-concentration (50 mg/mL), citrate-free formulation of Cyltezo has been commercially available since July 2023. “Biologics and biosimilars are a crucial treatment option for many living with psoriatic arthritis or psoriasis,” says Leah M.

Injections 36

Injections Clinic Safety Branding 36

Aesthetics Advisor

APRIL 26, 2024

As this substance infiltrates the American food supply, the potential risks to our health and future generations loom larger, raising urgent questions about the safety of our everyday food choices. In April of 2023, the EPA proposed allowing the first-ever use of chlormequat on barley, oat, wheat, and triticale grown in the United States.

Document 36

Document Safety Sales Diet 36

West Lake Dermatology

NOVEMBER 1, 2023

Updated on November 2, 2023 Undesirable arm contour can be a source of self-doubt, to the point where it affects our quality of life. Originally published on July 5, 2017. Loose upper arm skin is most often associated with some amount of weight loss.

Surgery 69

Surgery Scarring Consultations Consultation 69

Associated Skin Care Professionals

AUGUST 16, 2023

In addition to its goal of eliminating toxic beauty standards and empowering youth, the Dove Self Esteem Project also announced its plans to address the rise in youth mental health issues linked to social media with the Campaign for Kids Online Safety. 80% of young people believe people their age are addicted to social media. 

Social Media 40

Social Media Partnerships Branding Education 40

The Dermatology Digest

MARCH 11, 2024

This follows its designation as a Breakthrough Therapy for the treatment of pruritus associated with prurigo nodularis, originally granted in December 2019 and reconfirmed in March 2023. No new safety signals were observed in this trial.

Dermatitis 36

Dermatitis Safety Eczema Dermatology 36

The Dermatology Digest

JANUARY 4, 2024

The clinical results demonstrated that DMB-3115 and its reference product, ustekinumab, are highly similar, and have no clinically meaningful differences in terms of quality, safety and efficacy. In October of 2023, Accord BioPharma reached a settlement with Janssen Biotech Inc., commercialization.

Pharmaceutical 36

Pharmaceutical Partnerships Clinic Safety 36

The Dermatology Digest

FEBRUARY 7, 2024

The total duration of the trial was up to 24 weeks, which included a four-week screening period, a 16-week treatment period and a four-week safety follow-up period. and Janssen Biotech, Inc. The findings from the FRONTIER 1 clinical trial suggest the potential of JNJ-2113 across the spectrum of additional IL-23-mediated diseases.

Safety 36

Safety Clinic Office Dermatology 36

Aesthetics Advisor

APRIL 9, 2024

from 2023 to 2033. The market stands at a valuation of US 12 billion in 2023 and is expected to reach US 20 billion by 2033-end. Safety and side effects of olive oil Olive oil is generally safe and well-tolerated, but it may interact with certain medications (see Concerns and Cautions ). Let's dive in. What is avocado oil?

Marketing 36

Marketing Safety Extractions Medical 36

The Dermatology Digest

DECEMBER 18, 2023

The new AD guidelines also: • Highlight the safety of the topical calcineurin inhibitors with typical usage once or twice daily. The 2023 JTFPP atopic dermatitis guideline represents an advancement in trustworthy allergy guidelines,” says allergist Derek Chu, MD., Urge consideration for once-daily dosing of topical medications.

Dermatitis 36

Dermatitis Partnerships Therapy Diet 36

Aesthetics Advisor

FEBRUARY 21, 2024

I grabbed a ChatGPT account on the first day it was available in November 2023, because I recognized that it eclipsed the internet in terms of its revolutionary impact. For example, in October 2023, the U.S. Sources and References 1 The Conversation February 8, 2023 2 OpenAI Privacy Policy.

Tools 36

Tools Technology Legal Education 36

The Dermatology Digest

JULY 27, 2023

So we’re seeing some interesting trends,” said Patricia Farris, MD, who presented “Cosmeceutical Trends in 2023” at Music City SCALE 2024 symposium. “ So we just don’t have the standardization of what is being eliminated and no consensus as to what should be eliminated based on safety studies.

Sustainability 36

Sustainability Skincare Safety Ingredients 36

Aesthetic Advancements Institute (AAI)

JUNE 20, 2023

Juvéderm’s® newest filler, Volux , has been approved by the FDA and is set to hit medical offices in early 2023. There is a new dermal filler on the market! This new filler is designed to specifically target the jawline, an area of concern for many consumers seeking facial sculpting and contouring.

Training 36

Training Injections Medical Facials 36